The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary...
LOS ANGELES, June 30, 2026 /PRNewswire/ -- Zenerate, an AI-powered real estate feasibility platform, is pleased to announce a new partnership with AvalonBay Communities, Inc.,...
SALE INCLUDES STORIED GERMAN MESSERSCHMITT 109, E1 -WHICH DOCUMENTS DOWNED BRITISH RAF SPITFIRE AS "FIRST KILL" -AUGUST 10TH 1940 AND ANOTHER OVER ENGLAND, SEPTEMBER...